ライフサイエンスコーパス: cognitive symptom

1 tive symptoms) and decreased working memory (cognitive symptoms).

2 ttle is known about the neural basis of this cognitive symptom.

3 ation and might thereby produce negative and cognitive symptoms.

4 cacy, but it is unknown if ketamine improves cognitive symptoms.

5 for Alzheimer's disease before the onset of cognitive symptoms.

6 holinesterase inhibition therapy targets the cognitive symptoms.

7 ted at least 1 NPI symptom from the onset of cognitive symptoms.

8 in the previous month and from the onset of cognitive symptoms.

9 al nervous system, and some patients develop cognitive symptoms.

10 dard care in cancer survivors self-reporting cognitive symptoms.

11 vious 6 to 60 months and reported persistent cognitive symptoms.

12 de only partial amelioration of negative and cognitive symptoms.

13 d at reducing amyloid-have failed to reverse cognitive symptoms.

14 of the human brain, long before the onset of cognitive symptoms.

15 treating tardive dyskinesia and negative and cognitive symptoms.

16 ive function was only weakly associated with cognitive symptoms.

17 uit formation that cascade into more complex cognitive symptoms.

18 attention deficits that exacerbate its other cognitive symptoms.

19 CI 1.69 to 3.78), early dysphagia and early cognitive symptoms.

20 22q11.2 deletion-associated psychiatric and cognitive symptoms.

21 , is characterized by positive, negative and cognitive symptoms.

22 e of the striatum's potential involvement in cognitive symptoms.

23 regional patterns associated with motor and cognitive symptoms.

24 tic autonomic dysfunction prior to motor and cognitive symptoms.

25 disorder-60 years (27-91 years), eight with cognitive symptoms-69 years (62-89 years), eight with mi

26 owed a promising reduction in depressive and cognitive symptoms across all measures for NSI-189, with

27 In Huntington's disease (HD), cognitive symptoms and cellular dysfunction precede the

28 presentation, including behavior, mood, and cognitive symptoms and dementia.

29 ning, while CBT alone significantly improved cognitive symptoms and mental health functioning.

30 In healthy subjects without cognitive symptoms and patients with mild cognitive impa

31 duce a wide range of positive, negative, and cognitive symptoms and psychophysiologic deficits in hea

32 (ii) weighting of physical, behavioural and cognitive symptoms and signs; (iii) 'anterior' versus 'p

33 y designed trials that focus on the cardinal cognitive symptoms and their associated biomarkers in th

34 ioral or mood symptoms or both, 80 (95%) had cognitive symptoms, and 71 (85%) had signs of dementia.

35 ioral or mood symptoms or both, 23 (85%) had cognitive symptoms, and 9 (33%) had signs of dementia.

36 determined on the basis of medical history, cognitive symptoms, and exclusionary criteria.

37 ifficult to differentiate due to overlapping cognitive symptoms, and measures of apraxia, in particul

38 BT significantly improved fatigue, distress, cognitive symptoms, and mental health functioning, while

39 rst, before neurodegenerative biomarkers and cognitive symptoms, and neurodegenerative biomarkers bec

40 diseases characterized by pain, fatigue, and cognitive symptoms, and that affected patients may benef

41 ow SVD lesions contribute to neurological or cognitive symptoms, and the association with risk factor

42 early in the pathogenesis, and less so when cognitive symptoms appear.

43 Neuropsychiatric, or non-cognitive symptoms are increasingly recognized as manife

44 Cognitive symptoms are prevalent in PBC independent of l

45 Results from experiments in models of the cognitive symptoms associated with schizophrenia showed

46 c insights into the etiology of higher-order cognitive symptoms associated with the disease.

47 Cognitive symptoms at 12 months were reported in 25% of

48 e participants who received chemotherapy had cognitive symptoms at 6 months (32%) versus those who di

49 ntly associated with severity of fatigue and cognitive symptoms (both r2 = 0.3, P < .0001).

50 8242 may have a role in the treatment of the cognitive symptoms, but not the positive or negative sym

51 ate with disease stage in patients with mild cognitive symptoms, but this is not the case for CSF Abe

52 Alleviation of a range of cognitive and non-cognitive symptoms by drugs that modulate the cholinergi

53 ther the timing of onset nor the severity of cognitive symptoms can be accurately predicted.

54 a cluster, which was labeled as an emotional/cognitive symptom cluster.

55 mains related to the positive, negative, and cognitive symptom clusters of schizophrenia were affecte

56 ntervention, Insight, led to improvements in cognitive symptoms compared with standard care.

57 Cognitive symptoms, complex movement deficits, and incre

58 lack of effective treatment for negative and cognitive symptoms contribute to poor outcome.

59 Perceived cognitive symptoms correlated with objectively assessed

60 were standardized measures of pain, fatigue, cognitive symptoms, distress, and mental health function

61 physiological tasks relevant to the negative/cognitive symptom domains of schizophrenia that are thou

62 the early clinical stages as well as before cognitive symptoms emerge-during the long preclinical st

63 One of the cognitive symptoms experienced by schizophrenia patients

64 ain injury (TBI) survivors exhibit motor and cognitive symptoms from the primary injury that can beco

65 lar areas implicated for motor (PSP, MSA) or cognitive symptoms (FTD, ALS, PSP) in the diseases.

66 ntly with premorbid educational achievement, cognitive symptoms, global function, and illness duratio

67 rlier stages of the disease; even before any cognitive symptoms have appeared.

68 Studies of cognitive symptoms have commonly focused on prefrontal c

69 aracterized by persistent pain, fatigue, and cognitive symptoms, have been reported by many Gulf War

70 m, and impaired interference management is a cognitive symptom in many disorders.

71 multisensory integration is an understudied cognitive symptom in schizophrenia.

72 cs, modelling, and experimental treatment of cognitive symptoms in Alzheimer's disease.

73 Synaptic dysfunction is linked to cognitive symptoms in Alzheimer's disease.

74 for possible therapeutic amelioration of the cognitive symptoms in DS.

75 ssessing whether early AD is responsible for cognitive symptoms in geriatric patients: (a) a conventi

76 asticity could underlie the motor as well as cognitive symptoms in HD.

77 ns for the treatment of interference-related cognitive symptoms in neuropsychiatric disorders, partic

78 The histological underpinning of cognitive symptoms in older people has been demonstrated

79 cement, and in the treatment of positive and cognitive symptoms in patients with schizophrenia.

80 this study, we determined the prevalence of cognitive symptoms in PBC, examined the relationship bet

81 n disorders and shows promise in alleviating cognitive symptoms in some AD patients.

82 shed light on the prophylactic treatment of cognitive symptoms in the SZ.

83 The common cognitive symptoms include deficits in complex attention

84 alleviate behaviors that model negative and cognitive symptoms, including deficits in social interac

85 characterized by a high incidence of complex cognitive symptoms, including learning disabilities, att

86 Cognitive symptoms, like impaired cognitive control, are

87 rthritis self-efficacy for pain (P = 0.002), cognitive symptom management (P = 0.004), and communicat

88 sted healthy controls and patients with mild cognitive symptoms (N=331) in the BioFINDER study, using

89 ects was primarily characterized by mood and cognitive symptoms, not the classical neurovegetative si

90 nitive behaviors and could contribute to the cognitive symptoms observed in schizophrenia.

91 more prevalent and, for ALS, behavioural and cognitive symptoms occur more frequently.

92 lopmental disorder in which the emergence of cognitive symptoms occurs during early adolescence.

93 ecular mechanisms of neuronal dysfunction in cognitive symptoms of 22q11DS are poorly understood.

94 ay be a pathogenic event contributing to the cognitive symptoms of 22q11DS.

95 inhibitors are the primary treatment for the cognitive symptoms of Alzheimer disease (AD).

96 kinase (PAK) are suspected to play a role in cognitive symptoms of Alzheimer's disease (AD).

97 hylphenidate, are used as treatments for the cognitive symptoms of Alzheimer's disease and attention

98 ween brain overgrowth and the behavioral and cognitive symptoms of ASD is poorly understood.

99 In patients presenting with cognitive symptoms of dementia, regional brain metabolis

100 luated the role of the cholinergic system in cognitive symptoms of depression and unexpectedly observ

101 Somatic and cognitive symptoms of depression were assessed using the

102 srupted mesocortical dopamine contributes to cognitive symptoms of Parkinson's disease (PD).

103 s a promising candidate for the treatment of cognitive symptoms of patients with schizophrenia, in pa

104 t to the study of executive dysfunctions and cognitive symptoms of psychiatric disorders.

105 The cognitive symptoms of schizophrenia are largely resistan

106 The cognitive symptoms of schizophrenia presumably result fr

107 nd behavioral flexibility, components of the cognitive symptoms of schizophrenia, that are not rescue

108 this deficiency is pertinent to treating the cognitive symptoms of schizophrenia.

109 iduals that resemble positive, negative, and cognitive symptoms of schizophrenia.

110 e the potential to correct both positive and cognitive symptoms of schizophrenia.

111 le of addressing the positive, negative, and cognitive symptoms of schizophrenia.

112 n the endocannabinoid system account for the cognitive symptoms of schizophrenia.

113 ibution of early striatal dysfunction to the cognitive symptoms of schizophrenia.

114 What causes the positive, negative, and cognitive symptoms of schizophrenia?

115 gives rise to the debilitating emotional and cognitive symptoms of stress-related psychiatric disorde

116 e movement sleep behaviour disorder preceded cognitive symptom onset in six cases by a median of 10 y

117 Shorter disease duration from cognitive symptom onset to death was observed in men (be

118 Ds or related strategies could improve their cognitive symptoms or slow decline.

119 ely referred, nondemented patients with mild cognitive symptoms (original cohort, n = 118; validation

120 viding a potential mechanism for some of the cognitive symptoms produced by this mutation, our findin

121 ce patient, family, and clinicians when mild cognitive symptoms prompt a search for diagnosis and man

122 inor depression is characterized by mood and cognitive symptoms rather than neurovegetative symptoms;

123 ed to assess and probe for the more reliable cognitive symptoms such as anhedonia, guilt, suicidal th

124 n schizophrenic patients correlate with core cognitive symptoms, such as thought disorder and distrac

125 uropathology in olfactory brain areas before cognitive symptoms, suggesting the potential for olfacto

126 but could also serve as a substrate for the cognitive symptoms that comprise the early-stage patholo

127 nterneurons to MIA, leading to affective and cognitive symptoms that have high relevance for schizoph

128 potential ADAD, clinicians should note that cognitive symptoms typical of sporadic Alzheimer's disea

129 The prevalence of cognitive symptoms was determined in 198 patients with P

130 , bladder symptoms, gynaecological symptoms, cognitive symptoms, weight problems, vitality, and depre

131 Cognitive symptoms were frequent in our PBC population,

132 In the DIAN-OBS cohort, non-cognitive symptoms were more common at more severe stage

133 een shown to improve positive, negative, and cognitive symptoms when used as add-on therapy for the t

134 ipsychotics improved positive, negative, and cognitive symptoms, whereas the partial agonist D-cyclos

135 is associated with a variety of physical and cognitive symptoms which typically diminish during the f

136 d 118 patients aged 60 to 80 years with mild cognitive symptoms who underwent flutemetamol F 18 ([18F

137 t characteristics of LLD and overlap of some cognitive symptoms with other dementias.

138 Alzheimer's disease can exacerbate its other cognitive symptoms, yet relevant disruptions of key pref